2. Search Result
Search Result
Results for "

ER HER2- mammary carcinoma

" in MedChemExpress (MCE) Product Catalog:

2028

Inhibitors & Agonists

8

Screening Libraries

37

Fluorescent Dyes

64

Biochemical Assay Reagents

97

Peptides

5

MCE Kits

156

Inhibitory Antibodies

380

Natural
Products

88

Recombinant Proteins

55

Isotope-Labeled Compounds

90

Antibodies

20

Click Chemistry

34

Oligonucleotides

9

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50767
    Palbociclib
    235+ Cited Publications

    PD 0332991

    		 CDK Cancer
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib
  • HY-P9907
    Trastuzumab
    Maximum Cited Publications
    55 Publications Verification

    Anti-Human HER2, Humanized Antibody

    		 Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer [2] . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    Trastuzumab
  • HY-10261
    Afatinib
    100+ Cited Publications

    BIBW 2992

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [2] .
    Afatinib
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    55 Publications Verification

    Anti-Human HER2, Humanized Antibody (anti-HER2)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-50767C
    Palbociclib hydrochloride
    215+ Cited Publications

    PD-0332991 hydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib hydrochloride
  • HY-50767A
    Palbociclib monohydrochloride
    235+ Cited Publications

    PD 0332991 monohydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib monohydrochloride
  • HY-A0065
    Palbociclib isethionate
    230+ Cited Publications

    PD 0332991 isethionate

    		 CDK Infection Neurological Disease Cancer
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib isethionate
  • HY-P9912
    Pertuzumab
    5+ Cited Publications

    		 EGFR Cancer
    Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
    Pertuzumab
  • HY-164992
    Trastuzumab vedotin
    2 Publications Verification

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma [2].
    Trastuzumab vedotin
  • HY-P9912A
    Pertuzumab (anti-HER2)

    		EGFR Cancer
    Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
    Pertuzumab (anti-HER2)
  • HY-50767R
    Palbociclib (Standard)

    PD 0332991 (Standard)

    		 Reference Standards CDK Cancer
    Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib (Standard)
  • HY-P991149
    Nesfrotamig

    YH32367; ABL105

    		 TNF Receptor Cancer
    Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors [2] .
    Nesfrotamig
  • HY-164762
    Trastuzumab rezetecan

    SHR-A1811

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
    Trastuzumab rezetecan
  • HY-P99605
    Cinrebafusp alfa

    PRS 343

    		 EGFR TNF Receptor Cancer
    Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research [2].
    Cinrebafusp alfa
  • HY-P99030
    Margetuximab

    MGAH-22

    		 EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
    Margetuximab
  • HY-177008
    PROTAC HER2 degrader-1

    		PROTACs EGFR Apoptosis Akt ERK Cancer
    PROTAC HER2 degrader-1 is a highly selective HER2 PROTAC degrader, with a DC50 of 69 nM and a Dmax of 96%. PROTAC HER2 degrader-1 inhibits HER2-positive cell proliferation and tumor growth through persistent HER2 degradation and potent inhibition of downstream pathways (AKT and ERK). PROTAC HER2 degrader-1 induces apoptosis in BT-474 cells. PROTAC HER2 degrader-1 can be used for research of HER2-positive cancers. (Pink: HER2 ligand: (HY-177009); Black: Linker; Blue: CRBN ligand: (HY-W023573) .
    PROTAC HER2 degrader-1
  • HY-D2309
    IRDye700Dx (Maleimide)

    		Fluorescent Dye Photosensitizer Cancer
    IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells .
    IRDye700Dx (Maleimide)
  • HY-N1403
    Tigogenin

    		Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis [2] .
    Tigogenin
  • HY-P4082
    ErbB-2-binding peptide

    HER2-binding peptide

    		 EGFR Cancer
    ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .
    ErbB-2-binding peptide
  • HY-P990238
    Anti-Human/Rat HER2 (neu) Antibody (7.16.4)

    		EGFR Inflammation/Immunology Cancer
    Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 + T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer [2].
    Anti-Human/Rat HER2 (neu) Antibody (7.16.4)
  • HY-P99630
    Gancotamab antibody

    MM-302 antibody

    		 EGFR Cancer
    Gancotamab antibody (MM-302) is a HER2-targeted antibody with antitumor activity .
    Gancotamab antibody
  • HY-P10792
    HER2-targeted peptide H6F

    		EGFR Cancer
    HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
    HER2-targeted peptide H6F
  • HY-50767AR
    Palbociclib monohydrochloride (Standard)

    PD 0332991 monohydrochloride (Standard)

    		 CDK Reference Standards Cancer
    Palbociclib (monohydrochloride) (Standard) is the analytical standard of Palbociclib (monohydrochloride). This product is intended for research and analytical applications. Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib monohydrochloride (Standard)
  • HY-164763
    SHR-A1201

    		Antibody-Drug Conjugates (ADCs) EGFR Cancer
    SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .
    SHR-A1201
  • HY-143319
    SPH5030

    		EGFR Cancer
    SPH5030 is a selective and irreversible HER2 inhibitor. SPH5030 inhibits HER2 WT and EGFR WT with IC50s of 3.51 and 8.13 nM, respectively. SPH5030 shows excellent activities against HER2 mutants. SPH5030 can be used for the research of cancer .
    SPH5030
  • HY-P1855
    HER2/neu (654-662) GP2

    		EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers [2].
    HER2/neu (654-662) GP2
  • HY-W029411
    4-(Benzo[d]oxazol-2-yl)aniline

    		Drug Derivative Cancer
    4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent. 4-(Benzo[d]oxazol-2-yl)aniline has inhibitory activity against mammary carcinoma cell lines .
    4-(Benzo[d]oxazol-2-yl)aniline
  • HY-50767B
    Palbociclib dihydrochloride

    PD-0332991 dihydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib dihydrochloride
  • HY-P10569
    Biotin HER-2 substrate peptide

    		EGFR Cancer
    Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a Km value of 60 μm for Her2/neu kinase domain .
    Biotin HER-2 substrate peptide
  • HY-145960
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4

    		EGFR Toll-like Receptor (TLR) Inflammation/Immunology
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate .
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4
  • HY-106204
    Nelipepimut-S

    		EGFR Cancer
    Nelipepimut-S is a peptide vaccine which targets HER2. Nelipepimut-S has immune activity against HER2 positive breast cancer .
    Nelipepimut-S
  • HY-P991779
    Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19)

    		EGFR Cancer
    Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .
    Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19)
  • HY-178116
    HER2-IN-23

    		EGFR PARP Cancer
    HER2-IN-23 is a selective HER2 inhibitor. HER2-IN-23 reduces in total HER2 expression rather than in phosphorylated HER2 (p-HER2). HER2-IN-23 reduces cyclin D1 level and stimulates PARP cleavage. HER2-IN-23 can be used for the study of HER2-positive breast cancer .
    HER2-IN-23
  • HY-176744
    HER2-IN-22

    		EGFR Apoptosis Cancer
    HER2-IN-22 is a potent and selective HER2 inhibitor with an IC50 of 215 μM. HER2-IN-22 possesses killing activity against various tumor cells and can induce cell apoptosis. HER2-IN-22 significantly inhibits tumor growth. HER2-IN-22 can be used in the study for tumors such as HER2+ breast cancer .
    HER2-IN-22
  • HY-151162
    HER2-IN-12

    		EGFR Cancer
    HER2-IN-12 is a HER2 inhibitor (IC50: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .
    HER2-IN-12
  • HY-163418
    HER2-IN-17

    		EGFR Cancer
    HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC50 <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC50 <200 nM and amliorates non-small-cell lung cancer (NSCLC) .
    HER2-IN-17
  • HY-143733
    HER2-IN-5

    		EGFR Cancer
    HER2-IN-5 is a potent and orally active HER-2 inhibitor, example 10, extracted from patent WO2021164697 .
    HER2-IN-5
  • HY-174414
    EGFR/HER2-IN-18

    		EGFR Cancer
    EGFR/HER2-IN-18 is a stable EGFR/HER2 dual inhibitor with IC50 values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .
    EGFR/HER2-IN-18
  • HY-50767D
    Palbociclib orotate

    PD 0332991 orotate

    		 CDK Cancer
    Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib orotate
  • HY-145960A
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic

    		EGFR Toll-like Receptor (TLR) Inflammation/Immunology
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate .
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic
  • HY-P991234
    COVA208

    		EGFR p38 MAPK PI3K Akt Cancer
    COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .
    COVA208
  • HY-P10793
    Cyclic(YCDGFYACYMDV)

    		EGFR Apoptosis Cancer
    Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model .
    Cyclic(YCDGFYACYMDV)
  • HY-160087
    SG3376

    		EGFR Drug-Linker Conjugates for ADC Cancer
    SG3376 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). SG3376 is promising for research of HER2-overexpressing cancers (e.g., breast, gastric cancer) .
    SG3376
  • HY-168285
    LE01

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .
    LE01
  • HY-157399
    EGFR/HER2-IN-10

    		EGFR Cancer
    EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual EGFR/HER2 inhibitor with IC50s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .
    EGFR/HER2-IN-10
  • HY-143323
    HER2-IN-9

    		EGFR Cancer
    HER2-IN-9 is an orally active HER2 inhibitor, with an IC50 value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .
    HER2-IN-9
  • HY-151116
    HER2-IN-10

    		Apoptosis Cancer
    HER2-IN-10 is a psoralen derivative. HER2-IN-10 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-10 induces apoptosis .
    HER2-IN-10
  • HY-151118
    HER2-IN-11

    		Apoptosis Cancer
    HER2-IN-11 is a psoralen derivative. HER2-IN-11 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-11 induces apoptosis .
    HER2-IN-11
  • HY-144097
    HER2-IN-8

    		EGFR Inflammation/Immunology Cancer
    HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .
    HER2-IN-8
  • HY-163417
    HER2-IN-15

    		EGFR Cancer
    HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC50 <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC50 <200 nM and amliorates non-small-cell lung cancer (NSCLC) .
    HER2-IN-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: